Helix Biopharma Corp. (TSE:HBP) has released an update.
Helix BioPharma Corp., a clinical-stage biopharmaceutical company, has announced a private placement of CAD$1.915 million to support its immune-oncology therapy development. Additionally, the company is working to rectify the late filing of its interim financial statements, which has resulted in a management cease trade order by the Ontario Securities Commission, not affecting shareholder trading rights. The company assures there are no undisclosed material changes or insolvency proceedings currently underway.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
